Grace Therapeutics Inc. (GRCE)
NASDAQ: GRCE
· Real-Time Price · USD
3.26
0.18 (5.84%)
At close: Aug 15, 2025, 3:59 PM
3.26
0.02%
After-hours: Aug 15, 2025, 04:10 PM EDT
Grace Therapeutics Income Statement
Financials in USD. Fiscal
year is
April - March.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
Revenue | 8K | 8K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 115K | 196K | 196K |
Cost of Revenue | 4K | 5K | 6K | 5K | 5K | 4K | 3K | 2K | n/a | n/a | n/a | n/a | n/a | n/a | 40K | 76K | 76K |
Gross Profit | 1K | n/a | -6K | -5K | -5K | -4K | -3K | -2K | n/a | n/a | n/a | n/a | n/a | n/a | 75K | 120K | 120K |
Operating Income | -11.72M | -16.68M | -16.76M | -16.1M | -13.36M | -12.85M | -47.66M | -48.86M | -51.88M | -52.16M | -18.49M | -18.71M | -17.17M | -15.59M | -13.49M | -10.98M | -15.44M |
Interest Income | 477K | 712K | 794K | 972K | 1.01M | 911K | 849K | 600K | 424K | 322K | 249K | 222K | 200K | 188K | 104K | 102K | 103K |
Pretax Income | -12.79M | -12.77M | -16.44M | -14.28M | -13.71M | -14.69M | -48.59M | -50.15M | -51.52M | -51.97M | -18.57M | -18.18M | -12.12M | -10.47M | -11.56M | -11M | -18.13M |
Net Income | -10.31M | -9.57M | -13.37M | -11.61M | -11.45M | -12.85M | -38.77M | -40.27M | -41.93M | -42.43M | -17.25M | -17.14M | -11.22M | -9.82M | -11.56M | -11M | -18.13M |
Selling & General & Admin | 7.04M | 7.16M | 7.16M | 7.25M | 7.03M | 6.64M | 7.62M | 7.79M | 7.99M | 8.21M | 7.77M | 8.04M | 9.2M | 9.78M | 9.21M | 8.5M | 6.97M |
Research & Development | 7.76M | 9.51M | 9.56M | 8.81M | 6.3M | 4.68M | 4.64M | 5.64M | 8.48M | 9.97M | 10.66M | 10.39M | 7.68M | 5.56M | 3.69M | 2.19M | 2.89M |
Other Expenses | 5K | 6K | 39K | 38K | 37K | 1.52M | 35.41M | 35.43M | 35.41M | 33.97M | 54K | 283K | 295K | 249K | 662K | 413K | 5.71M |
Operating Expenses | 14.81M | 16.68M | 16.76M | 16.1M | 13.36M | 12.85M | 47.66M | 48.86M | 51.88M | 52.16M | 18.49M | 18.71M | 17.17M | 15.59M | 13.56M | 11.1M | 15.56M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | 75K | 75K | 75K | 75K | 147K | 147K | 147K | 147K | 264K | 264K | 264K |
Selling & Marketing Expenses | n/a | n/a | 61K | 91K | 91K | 91K | 81K | 123K | 126K | 136K | 340K | 346K | 343K | 333K | 144K | 292K | 225K |
Cost & Expenses | 11.72M | 16.68M | 16.76M | 16.1M | 13.36M | 12.85M | 47.66M | 48.86M | 51.88M | 52.16M | 18.49M | 18.71M | 17.17M | 15.59M | 13.6M | 11.17M | 15.64M |
Income Tax Expense | -2.48M | -3.2M | -3.07M | -2.67M | -2.27M | -1.83M | -9.81M | -9.88M | -9.59M | -9.54M | -1.32M | -1.04M | -890K | -648K | n/a | n/a | n/a |
Shares Outstanding (Basic) | 15.92M | 13.72M | 11.51M | 11.51M | 10.93M | 9.18M | 7.49M | 7.55M | 7.44M | 7.44M | 7.43M | 7.42M | 7.39M | 6.76M | 7.38M | 5.46M | 4.34M |
Shares Outstanding (Diluted) | 15.92M | 13.72M | 11.51M | 11.51M | 10.93M | 9.18M | 7.49M | 7.55M | 7.44M | 7.44M | 7.43M | 7.42M | 7.39M | 6.76M | 7.38M | 5.46M | 4.34M |
EPS (Basic) | -0.82 | -0.85 | -1.24 | -1.2 | -1.33 | -1.63 | -5.2 | -5.4 | -5.63 | -5.7 | -2.37 | -2.39 | -1.55 | -1.66 | -2.74 | -3.76 | -7.06 |
EPS (Diluted) | -0.82 | -0.85 | -1.24 | -1.2 | -1.33 | -1.63 | -5.2 | -5.4 | -5.63 | -5.7 | -2.37 | -2.39 | -1.55 | -1.66 | -2.74 | -3.76 | -7.06 |
EBITDA | -11.71M | -16.67M | -17.55M | -16.89M | -14.15M | -12.15M | -12.25M | -13.43M | -16.46M | -18.06M | -18.31M | -18.31M | -16.76M | -15.34M | -16.58M | -14.32M | -13.12M |
EBIT | -11.72M | -16.68M | -16.76M | -16.1M | -13.36M | -11.37M | -12.27M | -13.47M | -16.49M | -18.25M | -18.49M | -18.47M | -16.93M | -15.34M | -16.58M | -14.32M | -13.5M |
Depreciation & Amortization | 6K | 7K | 6K | 5K | 5K | 11K | 18K | 27K | -36K | 124K | 116K | 106K | 167K | n/a | 1K | 1K | 376K |